Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti–PD-1 Treatment-Naïve Advanced Melanoma

Antoni Ribas; Mohammed Milhem; Christopher Hoimes; Asim Amin; Cristopher Lao; Robert M. Conry; Jason P. Hunt; Gregory A. Daniels; Mohammed Almubarak; Montaser Shaheen; Theresa Medina; Minal Barve; Sarwan Bishnoi; Ehtesham Abdi; Michael Chisamore; Cristiana Guiducci; Jose Gomez-Romo; Albert Candia; Érick Gamelin; Robert L. Coffman; Robert S. Janssen; Georgina V. Long

doi:10.1158/1078-0432.ccr-25-0987

Abstract

In patients with anti-PD-1/PD-L1 treatment-naïve advanced melanoma, nelitolimod plus pembrolizumab induced objective responses, including in PD-L1-negative tumors. The treatment combination warrants further study in advanced melanoma.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Ribas et al. (2025) studied this question.

synapsesocial.com/papers/69dd67af7808b00a4799da0d https://doi.org/10.1158/1078-0432.ccr-25-0987

View at Publisher

Ask AI

Bookmark

Share

Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti–PD-1 Treatment-Naïve Advanced Melanoma

Abstract

Discussion

Cite This Study

Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti–PD-1 Treatment-Naïve Advanced Melanoma

Abstract

Discussion

Cite This Study

Keep reading

Keep reading